Unlocking two-fold LVV recovery with integrated affinity capture for high-productivity manufacturing

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Unlocking two-fold LVV recovery with integrated affinity capture for high-productivity manufacturing

Recovery losses across conventional clarification and capture steps remain a major bottleneck in lentiviral vector (LVV) manufacturing, limiting infectious particle yields and driving up process costs. This webinar presents new data on an affinity chromatography approach that delivers approximately two-fold higher recovery of infectious LVV particles compared with conventional anion exchange (AEX) membrane-based purification.

Attendees will see how a macroporous affinity resin architecture supports direct LVV capture from filtered tangential flow depth filtration (TFDF) perfusion permeate, removing the need for low-recovery clarification steps and streamlining downstream handling. The session will also examine the implications for process economics and for the transition toward continuous, intensified LVV manufacturing at scale.

Attend this webinar to:

Review comparative data showing two-fold higher recovery of infectious LVV particles versus conventional AEX membrane-based purification
Learn how direct affinity capture from filtered TFDF perfusion permeate can eliminate low-recovery clarification steps and reduce intermediate handling
Understand how integrating perfusion harvest with affinity capture supports the shift toward continuous, intensified LVV manufacturing
Explore how an integrated perfusion-to-affinity workflow can improve overall process economics for scalable cell and gene therapy production

Keen Chung

Technical Lead, Viral Vector Culture and Analytics at Repligen Corporation

Keen Chung, PhD, is technical lead for Viral Vector Culture and Analytics within R&D at Repligen. He has over ten years of industry experience in viral vector upstream process development and bioanalytical characterization for gene therapy manufacturing. Keen holds a PhD in Molecular Toxicology from the Penn State University College of Medicine and completed postdoctoral training at UT Southwestern Medical Center and SRI International. Prior to Repligen, he held scientific leadership roles at Pall Life Sciences, where he led analytical and upstream process development efforts supporting the optimization and scale-up of multiple viral vector manufacturing platforms. In his current role, Keen leads the development of advanced bioprocess technologies, with a focus on TFDF-based perfusion systems and viral vector analytics for cell and gene therapy applications.

In 24 Days

You have registered for this webinar